Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
May 2nd, 2019
7.3K views
Methods to prepare and characterize the physicochemical properties and bioactivity of neutrally-charged, pH-responsive siRNA nanoparticles are presented. Criteria for successful siRNA nanomedicines such as size, morphology, surface charge, siRNA loading, and gene silencing are discussed.
Overview
This article presents methods for preparing and characterizing neutrally-charged, pH-responsive siRNA nanoparticles. The protocol aims to enhance the bioavailability of siRNA for systemic administration in various disease treatments.
Key Study Components
Area of Science
- Nanomedicine
- Biophysics
- Gene Therapy
Background
- siRNA nanoparticles can improve gene silencing.
- Neutrally charged nanoparticles are suitable for systemic administration.
- Applications include treatment for cancer and autoimmune disorders.
- Characterization is crucial for ensuring suitability for animal studies.
Purpose of Study
- To produce siRNA-loaded nanoparticles.
- To characterize nanoparticles for effective administration.
- To enhance the therapeutic potential of siRNA.
Methods Used
- Dissolve polymer in ethanol to create a solution.
- Transfer polymer solution to citric acid buffer.
- Prepare siRNA solution in distilled water.
- Characterize size, morphology, and surface charge of nanoparticles.
Main Results
- Successful preparation of neutrally charged siRNA nanoparticles.
- Characterization confirms suitability for systemic administration.
- Demonstrated potential for treating various diseases.
- Enhanced bioavailability of siRNA observed.
Conclusions
- The protocol allows for effective production of siRNA nanoparticles.
- Characterization methods ensure nanoparticles meet necessary criteria.
- Potential applications in treating systemic diseases are significant.
Frequently Asked Questions
What are siRNA nanoparticles?
siRNA nanoparticles are carriers designed to deliver small interfering RNA for gene silencing in therapeutic applications.
Why are neutrally charged nanoparticles important?
Neutrally charged nanoparticles are less likely to trigger immune responses, making them suitable for systemic administration.
What diseases can be treated with siRNA nanoparticles?
They can potentially treat various diseases, including cancer, cardiovascular diseases, and autoimmune disorders.
How are the nanoparticles characterized?
Characterization involves assessing size, morphology, surface charge, and siRNA loading capacity.
What is the significance of this protocol?
It provides a reliable method for producing and characterizing siRNA nanoparticles for research and therapeutic use.
Executive Industry Relevance
Efficient cytosolic delivery of siRNA remains a critical bottleneck in translating RNAi therapeutics to non-hepatic tissues such as tumors. This protocol enables the preparation and characterization of neutrally-charged, pH-responsive polymeric nanoparticles that enhance siRNA bioavailability and support systemic administration. By providing a standardized method for physicochemical and biological validation, the approach facilitates preclinical evaluation of siRNA therapeutics targeting undruggable disease pathways.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional validation of siRNA-mediated gene knockdown in relevant cellular models.
- Operational Value: Supports rapid, high-throughput assessment of siRNA bioactivity using luciferase reporter assays.
- Predictive Value: Confirms endosomal escape capability via pH-responsive membrane lytic activity, de-risking mechanistic hypotheses.
Screening & Assay Development
- Scientific Value: Provides quantitative size, surface charge, and morphology data essential for nanoparticle screening cascades.
- Operational Value: Standardizes characterization via dynamic light scattering, TEM, and agarose gel retardation for reproducible batch evaluation.
- Predictive Value: Identifies optimal nitrogen-to-phosphate ratios for maximal siRNA complexation and colloidal stability.
Translational & Preclinical Research
- Scientific Value: Demonstrates cytosolic siRNA delivery and gene silencing efficacy in vitro, supporting translational readiness.
- Operational Value: Establishes QC benchmarks (neutral charge, <100 nm size, monodisperse distribution) for progression to animal studies.
- Predictive Value: Reduces late-stage failure risk by confirming endosomal escape and bioavailability prior to in vivo testing.
Pipeline & Workflow Integration
The method integrates into the siRNA therapeutic workflow from early discovery through preclinical validation, enabling iterative design-test cycles for nanoparticle optimization.
- Discovery Biology: Facilitates hypothesis testing of gene targets via reliable siRNA delivery and measurable knockdown in model systems.
- Screening: Delivers standardized nanoparticle formulations with defined physicochemical properties for consistent compound or nucleic acid evaluation.
- Analytics: Generates multiparametric readouts (size, zeta potential, morphology, gel shift, luminescence) that inform structure-function relationships.
- Translational Research: Bridges in vitro validation to preclinical studies by ensuring nanoparticles meet critical delivery criteria.
- Enterprise Reuse: Establishes a platform-compatible protocol adaptable to various siRNA sequences and disease targets.
Operational & Enterprise Impact
- Scientific Value: Mechanistic de-risking through confirmation of pH-triggered endosomal escape and cytosolic siRNA release.
- Operational Value: Reproducible production of neutrally charged nanoparticles suitable for systemic administration and GMP-compatible scaling.
- Strategic Value: Improves go/no-go decisions by linking nanoparticle design to functional gene silencing outcomes.
- Portfolio Impact: Enables risk-adjusted prioritization of siRNA candidates based on delivery efficiency and bioavailability.
Implementation Considerations
- Expertise in polymer chemistry, nucleic acid handling, and nanoparticle characterization techniques.
- Access to dynamic light scattering, transmission electron microscopy, agarose gel electrophoresis, and luminescence plate readers.
- Standardization of buffer conditions and nitrogen-to-phosphate ratios across production batches.
- Adaptation considerations for different siRNA lengths, sequences, and polymer block ratios.
- Limitations include potential aggregation at high polymer concentrations and the need for empirical optimization of loading conditions.
Biopharma FAQs
Why does nitrogen to phosphate ratio matter for siRNA nanoparticle complexation?
The nitrogen to phosphate ratio determines the extent of siRNA binding to the polymer, with higher ratios leading to decreased free siRNA band intensity in agarose gel retardation assays, indicating increased complexation and colloidal stability of the nanoparticles.
How does dynamic light scattering inform nanoparticle suitability for systemic administration?
Dynamic light scattering measures hydrodynamic diameter and polydispersity index, confirming unimodal size distribution (<35 nm) and near-zero zeta potential, which are critical for avoiding rapid clearance and ensuring long circulation time in vivo.
What does agarose gel retardation reveal about siRNA loading efficiency?
Agarose gel retardation shows siRNA band disappearance at the gel bottom when complexed to polymer, demonstrating that siRNA is sequestered within the nanoparticle core and unavailable for migration, which correlates with high loading efficiency and protection from nucleases.
Why is endosomal escape validation critical for siRNA nanoparticle efficacy?
Endosomal escape is validated by the pH-responsive membrane lytic activity of the DB block below pH 6.8, which triggers release of siRNA into the cytosol, enabling engagement with the RNAi machinery and measurable gene silencing in luciferase assays.
How does luciferase assay output support go/no-go decisions in siRNA nanoparticle development?
Luciferase assay quantifies gene knockdown efficacy, where significant reduction in luminescence relative to scrambled control confirms bioactive siRNA delivery, while lack of signal change indicates formulation failure and informs design iteration prior to preclinical investment.
Chapters in this video
0:04
Title
0:49
Preparation and Characterization of si-NPs (siRNA Nanoparticles)
2:00
Physicochemical Characterization of si-NPs
5:04
Determining in vitro Bioactivity of si-NPs
6:35
Results: Comparison between si-NP 1 and si-NP 2 and siRNA Complexation
8:29
Conclusion
